ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
Globe Newswire•05/10/2026•16:01 ET
0
Key Highlights
- ➤Cancer Research UK will fully fund and sponsor ORIC-259’s CTA-enabling studies and Phase 1/2 development
- ➤ORIC retains an option to reacquire ORIC-259 rights after Phase 1/2 data
- ➤ORIC-259 is a potential first-in-class oral mRNA degrader targeting previously undruggable CIP2A
- ➤Cancer Research UK may receive downstream milestones and royalties under the agreement
Expert Statements
Lori Friedman, Chief Scientific Officer of ORIC Pharmaceuticals
“We are excited to partner with Cancer Research UK to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into the clinic”
Lars Erwig, Director of Cancer Research UK’s Centre for Drug Development
“ORIC-259 represents an innovative approach to targeting CIP2A, a protein with significant potential in cancer but one that has proven difficult to drug”
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target
Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development
Get started
Create a free account to read the full story.